Bernhard Sakmman, M.D.

For Corporates
Insights into Healthcare M&A: Q3 2024 Trends
Healthcare M&A activity increased in the third quarter of 2024, with 33 transactions vs. 21 in 2023. Healthcare Services was the most active healthcare subsector, representing 42% of deal volume, with the most notable transaction being TowerBrook’s and CD&R’s $8.3B acquisition of R1 RCM. Biopharma transaction volume increased slightly in the third quarter of 2024, with 10 transactions vs. 9 in 2023, while transaction value declined from $13 billion to $9 billion. Oncology was the most active therapeutic area. We expect Biopharma M&A activity to remain dynamic as large biopharmaceutical companies seek to fill revenue and pipeline gaps via acquisitions of development-stage companies. We continue to expect both private and publicly traded pre-commercial biopharma companies to evaluate the full range of strategic alternatives, including partnerships, mergers and sale transactions. Given an improving macroeconomic backdrop and corresponding capital markets environment, we also expect private development-stage private companies to increasingly evaluate IPOs.
LEARN MORE
For Investors
Sectors
Insights
About
- Firm
- Careers
- News
- Contact
- Transactions

Team
Banking
Bernhard Sakmman, M.D.

Bernhard Sakmann, M.D., is a Senior Managing Director in Investment Banking at Leerink Partners covering the Medical Technology and Life Science Tools and Diagnostics sectors.

Prior to joining the Firm in 2024, Bernhard was most recently a Senior Managing Director at Evercore, providing strategic and financial advice to life science companies with a focus on medical technology and life science tools and diagnostics. Prior to joining Evercore in 2014, Bernhard spent over a decade in healthcare investment banking and in management consulting with Citigroup, Lehman Brothers and Oliver Wyman in New York and in London. Notable transactions for which Bernhard has been an adviser include Philips on its acquisitions of Biotelemetry and Capsule, GE on its acquisition of BK Medical and spin of GE Healthcare, Abbott on its acquisitions of St Jude Medical and Alere, Terumo on its acquisitions of Sequent Medical and Bolton Medical, Immucor on its sale to Werfen, Decipher on its sale to Veracyte, ArcherDx on its sale to Invitae, Brooks Automation on its acquisitions of Genewiz and BioStorage Technologies, among many others.

He received a Doctorate in Medicine from Ludwig-Maximilians-University, Munich, Germany, a B.M. BCh. from Oxford University, UK, and a B.A. and an M.A. in Natural Sciences from Cambridge University, UK.

Partner With Us

Contact Us